
STRO Stock Forecast & Price Target
STRO Analyst Ratings
Bulls say
Sutro Biopharma Inc. has demonstrated a strong commitment to innovating in the field of antibody-drug conjugates (ADCs), with promising candidates such as STRO-004, which has preclinical data suggesting improved potency and safety compared to existing therapies. The company's robust pipeline, featuring multiple product candidates aimed at addressing unmet medical needs in oncology and autoimmune disorders, further signifies its strategic advantage in a competitive market. Additionally, the potential for STRO-004 to synergize with other treatments like immunotherapies positions Sutro favorably for significant market share and enhanced patient acceptance, contributing to an optimistic outlook for the company's financial future.
Bears say
Sutro Biopharma Inc faces significant challenges related to the tolerability of its antibody-drug conjugates (ADCs), as ocular toxicity concerns are hindering physician adoption and patient treatment agreements. Reports indicate that 15-20% of patients experience treatment interruptions due to treatment-related adverse events (TRAEs), particularly involving ocular issues, which lead to extended delays in receiving care from specialized ophthalmologists. Furthermore, while the company's platform targets pseudokinases, which are linked to poor treatment outcomes and resistance in various tumors, the uncertain role of these targets in cancer biology adds to the potential risks impacting the company’s future performance and stock valuation.
This aggregate rating is based on analysts' research of Sutro Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.
STRO Analyst Forecast & Price Prediction
Start investing in STRO
Order type
Buy in
Order amount
Est. shares
0 shares